new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib)
January 2013
You'll hear about a new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib).
Xeljanz is the first Janus kinase (JAK) inhibitor. Janus kinases are enzymes linked to inflammation in joints and other tissues.
It's not a first-line agent. It's for patients who have failed or can't tolerate methotrexate. It can also be added to methotrexate or other DMARDs...but not biologics (Humira, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote